Pulse Biosciences wins FDA approval for AF study using nsPFA technology
September 9, 2025
The trial will evaluate the effectiveness of the nsPFA cardiac surgical system during concurrent surgical procedures.
The trial will evaluate the effectiveness of the nsPFA cardiac surgical system during concurrent surgical procedures.
Neurescue’s device is claimed to be the first catheter to have received a CE mark for addressing non-shockable cardiac arrest.
The company has completed registration and certification for its total disc replacement products, which are now CE-marked.
Johnson & Johnson (NYSE:JNJ) announced today that the FDA approved Inlexzo, its gemcitabine intravesical drug delivery system.
Neurescue announced today that it received CE mark approval for its device designed to treat non-shockable cardiac arrest.
Varian announced its Embozene microspheres have received CE mark for genicular artery embolisation (GAE) to treat knee osteoarthritis.
The FDA’s clearance of LIBERTY follows the completion of Microbot’s pivotal trial in April 2025, achieving a 100% success rate in robotic navigation.
ARC‑EX is the first system to receive a CE Mark in Europe specifically for improving hand and arm strength and sensation in adults with chronic, incomplete spinal cord injury.
Pulse Biosciences (Nasdaq:PLSE) announced today that the FDA granted investigational device exemption (IDE) for its nanosecond pulsed field ablation (nsPFA) system.
Lifeward (Nasdaq:LFWD) announced today that it received CE mark approval for its ReWalk 7 personal exoskeleton.